Vaxart, Inc. develops oral recombinant pill vaccines based on a proprietary delivery platform. The clinical-stage biotechnology company’s programs include vaccine candidates for coronavirus, norovirus and influenza, as well as a therapeutic human papillomavirus vaccine as its first immune-oncology indication. Its pill-based vaccines are designed for oral administration, storage and shipping without refrigeration, and avoidance of needle-stick risk.
Vaxart news centers on clinical data and scientific publications, business updates, financial results, financing arrangements, collaborations, intellectual property around adenovirus and TLR3 agonist oral vaccination technology, and governance changes as the company advances its oral vaccine pipeline.
Vaxart (NASDAQ: VXRT) will host two webcasts: a Full Year 2025 Business Update and Financial Results call on March 12, 2026 at 4:30 p.m. ET, and a Stockholder Fireside Chat on March 13, 2026 at 4:30 p.m. ET.
Both events will be webcast live on the company website, include senior management participation, accept investor questions in advance via ir@vaxart.com, and will be available on replay after the events.
Vaxart (OTCQX: VXRT) announced that management will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Wednesday, February 25, 2026 at 4:00 PM ET.
The virtual presentation will be webcast and available on the company investor relations website for 30 days following the event; management will also hold one-on-one meetings.
Vaxart (OTCQX: VXRT) published Phase 1, double-blind, placebo-controlled data showing a single-dose oral bivalent norovirus vaccine was safe and well-tolerated in lactating women and induced norovirus-specific antibodies in serum and breast milk.
The study reported norovirus-specific IgA in breastfed infants' stool that correlated with breast milk IgA, suggesting passive transfer of mucosal immunity to infants. Results were published in npj Vaccines on Jan 15, 2026.
Vaxart (OTCQX: VXRT) will present at the virtual Global BioInnovation Forum on Tuesday, January 13, 2026. Senior leaders speaking are Steven Lo (CEO), Sean Tucker, Ph.D. (Founder & Chief Scientific Officer) and James F. Cummings, M.D. (Chief Medical Officer).
The presentation is scheduled for 11:30am PT / 2:30pm ET. A live webcast will be available via the company's investor relations website and will remain accessible for 30 days after the event.
Vaxart (OTCQX: VXRT) reported Q3 2025 results and a business update on Nov 13, 2025. Key items: an exclusive license and collaboration with Dynavax for the oral COVID-19 pill vaccine (upfront $25M plus $5M equity; potential cumulative proceeds up to $700M plus royalties); completion of enrollment of ~5,400 participants in the Phase 2b COVID-19 trial with topline data expected in late 2026 and a 400-person sentinel cohort readout expected in Q1 2026.
Financials: $28.8M cash/investments as of Sept 30, 2025 and runway into Q2 2027; Q3 revenue $72.4M; R&D expense $75.9M; net loss $8.1M.
Vaxart (OTCQX: VXRT) will host two investor webcasts in November 2025. Management will report third quarter 2025 financial results after market close on Thursday, November 13, 2025 and hold a conference call at 4:30 p.m. ET. A stockholder fireside chat is scheduled for Tuesday, November 18, 2025 at 4:30 p.m. ET / 1:30 p.m. PT to answer shareholder questions.
Both events will be webcast on the company website and replayed afterward. Investors can call in using the provided domestic and international numbers for the Nov. 13 call, and may submit questions in advance to ir@vaxart.com or via the webcast portal.
Dynavax (NASDAQ: DVAX) reported Q3 2025 results and announced a new $100 million share repurchase program on Nov 5, 2025. HEPLISAV-B quarterly net product revenue was $90.0M, up 13% YoY, with U.S. total market share ~46% and retail share ~63%. Full-year HEPLISAV-B guidance remains $315–$325M. GAAP net income was $26.9M and adjusted EBITDA was $35.5M for Q3. Cash, cash equivalents and marketable securities totaled $647.8M at Sept 30, 2025. Dynavax entered an exclusive license with Vaxart for an oral COVID-19 vaccine (upfront $25M + $5M equity; $50M contingent payment after Phase 2b), and presented positive topline Phase 1/2 shingles data for Z-1018 at IDWeek.
Dynavax (Nasdaq: DVAX) entered an exclusive worldwide license for Vaxart's oral COVID-19 vaccine program on Nov 5, 2025, paying a $25M upfront license fee plus a $5M equity investment. Vaxart will fund and run the ongoing Phase 2b trial (≈5,400 participants) through an EOP2 meeting with FDA; topline data are expected in late 2026. After the Phase 2b readout Dynavax may elect to assume development, paying an additional $50M and potential milestones up to $195M (regulatory) and $425M (sales) plus low‑to‑mid‑teens royalties.
Vaxart (OTCQX: VXRT) will present research on its second-generation norovirus oral pill vaccine candidate at IDWeek 2025 in Atlanta, held October 19–22, 2025.
The presentation, titled “An Open-Label Phase 1 Clinical Trial Demonstrating Improved Immune Responses to Norovirus Strains GI.1 and GII.4 from a Next Generation Oral Bivalent Vaccine Candidate”, is scheduled for Monday, October 20, 2025, 1:45 PM–3:00 PM ET in room B401-B402 and will be delivered by Nicholas J. Bennett, MBBChir, PhD.
Vaxart (OTCQX: VXRT) will present clinical updates on its oral norovirus and COVID-19 pill vaccine programs at World Vaccine Congress Europe 2025 in Amsterdam on October 13–16, 2025. Two presentations by Dr. Sean Tucker will cover a bivalent oral norovirus vaccine with recent immunogenicity improvements and a clinical update on the oral COVID-19 vaccine covering Phase 1 to Phase 2 data.
The company highlights that its oral recombinant pill platform has generated both systemic and mucosal immune responses and shown a favorable safety and tolerability profile in clinical trials, positioning these programs as ongoing clinical-stage efforts toward potential global public-health solutions.